Beijing Beilu Pharmaceutical Co., Ltd
300016.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.33B
Close$
$-3.31
140.9% downside
Current Fair Value
140.9% downsideOvervalued by 140.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.33 Billion |
|---|---|
| Enterprise Value | $5.51 Billion |
| Dividend Yield | $0.06 (0.66%) |
| Earnings per Share | $0.18 |
| Beta | 0.28 |
| Outstanding Shares | 579,605,638 |
Return
| Return on Equity | 5.71% |
|---|---|
| Return on Assets | 3.95% |
| Return on Invested Capital | 6.47% |
Valuation & Multiples
| P/E Ratio | 36.15 |
|---|---|
| PEG | 28.83 |
| Price to Sales | 4.06 |
| Price to Book Ratio | 2.03 |
| Enterprise Value to Revenue | 4.26 |
| Enterprise Value to EBIT | 28.4 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Beijing Beilu Pharmaceutical Co., Ltd
1,188 employees
CEO: Xu Wang Beijing Beilu Pharmaceutical Co., Ltd., established in 1992 and headquartered in Beijing, China, operates within the pharmaceutical industry. The company is primarily involved in the research, development, production, and commercializati...